Ask about this productRelated genes to: SENP2 Blocking Peptide
- Gene:
- SENP2 NIH gene
- Name:
- SUMO specific peptidase 2
- Previous symbol:
- -
- Synonyms:
- SMT3IP2, KIAA1331, DKFZp762A2316, AXAM2
- Chromosome:
- 3q27.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-11
- Date modifiied:
- 2018-02-23
Related products to: SENP2 Blocking Peptide
Related articles to: SENP2 Blocking Peptide
- Mitochondrial damage and subsequent aberrant mitophagy are critical drivers of alveolar simplification in bronchopulmonary dysplasia (BPD). E26 transformation specific-1 (ETS1) is a transcription factor whose role in BPD and its regulation of mitophagy have not been fully investigated. This study aims to explore the role of ETS1 in mitophagy in BPD and its underlying molecular mechanisms. Using hyperoxia-induced BPD models in cells and mice, we found that ETS1 overexpression simplified alveolar structure, reduced alveolar number, inhibited mitophagy, improved cell viability and mitochondrial damage. Mechanistically, EST1 promoted the transcription of SENP2. After SENP2 removed the SUMO1 modification from FUNDC1, the binding site of HSPA8 was exposed, thereby promoting the degradation of FUNDC1. In BPD mice, ETS1 overexpression alleviated lung injury and inhibited mitophagy, while SENP2 knockdown reversed these effects. In conclusion, ETS1, as a novel transcriptional hub, maintained mitochondrial homeostasis by coordinating the deSUMOylation-coupled FUNDC1 degradation pathway. ETS1 blocked mitochondrial damage-induced mitophagy by targeting the SENP2/HSPA8/FUNDC1 axis, providing a promising strategy for the treatment of BPD. - Source: PubMed
Publication date: 2026/04/30
Yang MinYang QinglanMeng YanniZhang JiyanLi Shuangjie - The genetic basis of cardiovascular-kidney-metabolic syndrome (CKMs) involves complex pleiotropy, necessitating analytical approaches capable of dissecting shared genetic architectures across multiple cardiometabolic traits. - Source: PubMed
Lu ChuanlongLi LizhengChen JinshanChang RunzeDong Honglin - To investigate the molecular mechanisms, functional controversies, and clinical significance of Fibroblast Growth Factor 21 (FGF21) in the context of breast cancer. - Source: PubMed
Publication date: 2026/03/11
Chen JialiChang ChengyaoYang Xuan - Ubiquitin-specific proteases (USPs) play a critical role in the development of various cancers. The study aimed to elucidated the pathogenic molecular mechanisms and analyze its clinical significance in esophageal squamous cell carcinoma (ESCC). - Source: PubMed
Publication date: 2025/11/17
Wu HaiboZhang XinkeZhou ZhengyiChen KemingChen JierongMa ChaoDuan JinlingLi YingqingChen Jiewei - Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive and heterogeneous haematological malignancy with poor outcomes, underscoring the need for novel therapeutic targets to improve remission rates. SUMO (small ubiquitin-related modifier)-specific protease 2 (SENP2) has been demonstrated to exert pleiotropic functions across diverse physiological processes and oncogenic transformation. Nevertheless, its precise function in DLBCL has rarely been investigated. Our research revealed that SENP2 was markedly overexpressed in DLBCL and its elevated levels were correlated with unfavourable prognosis. Furthermore, we constructed an integrative nomogram incorporating SENP2 expression and the International Prognostic Index score, which demonstrated robust predictive performance. Subsequently, SENP2 was validated to critically promote DLBCL cell proliferation both in vitro and in vivo. To investigate the underlying mechanisms, we performed RNA sequencing coupled with tumour infiltrating immune cells analysis, revealing that SENP2 knockout reduced myeloid-derived suppressor cell accumulation while simultaneously enhancing both the infiltration and functional activation of CD8 T cells. Finally, we performed virtual screening of Food and Drug Administration-approved drugs against SENP2, followed by re-docking analysis and identified four of the most promising candidates. Collectively, our findings characterized SENP2 as a novel prognostic biomarker and a promising therapeutic target in DLBCL. - Source: PubMed
Publication date: 2025/10/01
Sheng XueWang DongmeiLi ShuyingLi BoyaLuan MengfanHan XiaoZhou QiruiZhao ZheJi ChunyanLu FeiYe Jingjing